title: Regulatory effect of cytokine production in patients with cerebral infarction by Yulda-Hanso-Tang.
abstract: Yulda-Hanso-Tang (YH-Tang) is a prescription for the Taeumin cerebral infarction (CI) patients according to Sasang constitution philosophy. Taeumin patients with CI were treated with YH-Tang during the acute stage. Clinical signs of CI disappeared markedly in about 2 weeks after oral administration of YH-Tang in all patients. The mean interleukin (IL)-2 serum levels were lower in the patients with CI than in the normal groups, whereas the mean IL-4, IL-6 and IgE levels were significantly higher in the patients. There were no significant differences in interferon-gamma (IFN-gamma) levels between the groups. Serum IFN-gamma and IL-2 levels derived from T helper (Th)1 cells elevated significantly in the patients with CI by YH-Tang administration. Significant reduced serum levels of IL-4 and IL-6 derived from Th2 cells and IgE were observed in the patients treated with YH-Tang. During the period of YH-Tang administration, there were no other adverse effects. The data indicate that YH-Tang has a good CI treatment effect, and that its action may be due to regulation of cytokine production.
authors.affiliation: Department of Oriental Pharmacy, College of Pharmacy and Center of Oriental Medical Science, Iksan-city, Chonbuk, South Korea.
authors.forename: H Y
authors.initials: HY
authors.lastname: Shin
authors.forename: H J
authors.initials: HJ
authors.lastname: Jeong
authors.forename: J H
authors.initials: JH
authors.lastname: Lee
authors.forename: J C
authors.initials: JC
authors.lastname: Joo
authors.forename: K Y
authors.initials: KY
authors.lastname: Kim
authors.forename: H J
authors.initials: HJ
authors.lastname: Song
authors.forename: S G
authors.initials: SG
authors.lastname: Lee
authors.forename: H J
authors.initials: HJ
authors.lastname: Chae
authors.forename: H R
authors.initials: HR
authors.lastname: Kim
authors.forename: J J
authors.initials: JJ
authors.lastname: Kim
authors.forename: H M
authors.initials: HM
authors.lastname: Kim
mesh_terms: D002544:Cerebral Infarction / Q000188:drug therapy* / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis* / Q000097:blood; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D007371:Interferon-gamma / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D015847:Interleukin-4 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology
chemical_list: D016207:Cytokines; D004365:Drugs, Chinese Herbal; D007376:Interleukin-2; D015850:Interleukin-6; D015847:Interleukin-4; D007073:Immunoglobulin E; D007371:Interferon-gamma